Abstract
Introduction:
Breast cancer is the most common cancer worldwide. It is the second major cause of cancer deaths among women in the United States. 1 According GLOBOCAN estimates, more than half (52.9%) of the 1.67 million new breast cancer cases were diagnosed in developing countries in 2012. 1 South Asia, the home of approximately 588 million women over 15 years of age, 2 facing a growing breast cancer epidemic as the incidence of breast cancer is increasing dramatically. 3 Although Bangladesh has made enormous progress in the health sector, especially related to infectious diseases, 4 the issue of cancer is given less priority at both policy and research level. 5 Not much information on breast cancer in Bangladesh is available. According to National Institute of Cancer Research and Hospital report, 5255 breast cancer cases were diagnosed during the period 2005-2010. Providing quality care to these huge number cancer cases is really a challenge.
In the last two decades the treatment of breast cancer has changed a lot. For better prediction of a patient's response to endocrine therapy and their prognosis, biological markers hormone receptor status is now essential. The estrogen receptor (ER), progesterone receptor (PR), and proto-oncogene HER2/neu (HER2) profile of a female primary breast carcinoma plays a significant role as a predictive marker in patient management. Current therapeutic strategies for management of primary breast carcinomas rely on the accurate immunohistochemical (IHC) determination of hormone receptor status in order to determine the clinical utility of hormone-directed therapies such as selective estrogen receptor modulators (SERMs). For example, multiple major clinical trials conducted by the National Surgical Adjuvant Breast and Bowel Project have shown that addition of Tamoxifen, a SERM, to conventional chemotherapeutic and surgical treatment protocols consistently improves disease free survival in women with hormone receptor-positive tumors. 6 Patients with tumors that are diagnosed with positive ER and/or PR status have lower risks of mortality compared to women with negative ER and/or PR disease. [7] [8] [9] [10] [11] Clinical trials have also demonstrated that the survival advantage for women with hormone receptor-positive tumors is increased by treatment with adjuvant hormonal and/or chemotherapeutic regimens. 12 HER2-neu, which encodes a receptor tyrosine kinase, is amplified and over-expressed in 20-25% breast cancers and such tumors are often resistant to hormone therapy. 13 However, data on breast cancer markers including ER, PR and Her2/neo expression are scarce. None of the public hospitals except NICRH have the marker testing facilities in general. Only three private clinics/hospitals offer breast cancer marker testing services, mainly for affluent people (BSMMU). A retrospective study on 1042 breast cancer cases demonstrated that 69% and 73% of the cases were ER + and PR + respectively. About 28% of cases showed Her2/neu overexpression and 9% had triple negative breast cancer (TNBC). 14 However, no special attention has been given on hormone receptor status of breast cancer in the Public Health Sector of Bangladesh. The present study was, therefore, designed to evaluate the biological markers that are commonly assessed with breast cancer to predict a patient's response to endocrine therapy and their prognosis for better clinical outcomes.
Patients and Methods:
This cross-sectional study was conducted in the Department of Pathology, Dhaka Medical College, Dhaka over a period 12 months July 2009 to June 2010. A total of 30 histopathologically diagnosed cases of breast tumors who were also subjected to immunohistochemical (IHC) test for ER, PR and HER-2/neu status were consecutively included in the study. The goal of determining the receptor status is not only to predict prognosis but also to decide its treatment (that is providing right treatment to the right patient). This hormone receptor status is graded using Allred 15 scoring and grading system. Depending on the hormone status, breast carcinomas were divided into a number of different categories ranging from ER, PR, HER2/ neu positive and triple positive through triple negative.
The data were collected on a structured questionnaire containing the variables of interest. patients having primary ductal and lobular breast carcinoma were evaluated for their receptor status. The pathology reports were reviewed for patient's demographics, side of breast involved, location and size of tumor, lymph node involvement, histological grade and differentiation of carcinoma according to World Health Organization (WHO) classification of breast tumours 16 .
Result:
Age distributions shows that 40% of the patients were early middle-aged (30-40 years), 30% middle-aged and the rest were either < 30 years or >50 years old. Left breast was involved more often (56.7%) than the right breast (43.3%). The predominant location was upper outer quadrant (43.3%), followed by upper inner quadrant (20%), lower outer quadrant (20%), lower inner quadrant (10%) and central (6.7%). Over half (53.3%) of the tumors were < 5 cm and the rest 5 cm or more (Table I) . Nearly half (46.7%) of the tumors were moderately differentiated, 36.6% welldifferentiated and 16.7% poorly differentiated (Table II) . In majority (83.3%) of the cases lymph-nodes were involved. In terms of receptor status, more than half (53.3%) of the tumors were ER and PR positive and 40% were Her2/neu overexpressed (Table III) . 
Discussions:
In the present study over half (53.3%) of the breast carcinoma cases were positive for estrogen and 17 Nadji and associates 18 reported positive nuclear staining for ER and PR in 75 and 55% of invasive carcinomas respectively. The wide difference in the ER status between their findings and the findings of the present study might be that these tests were conducted on 30 cases only, while Nadji and associates conducted these tests on 5,993 cases of breast cancer. In neighboring state of India (West Bengal), about 57% of breast cancer patients were ER-positive, while 22% of the cases were triple-negative. 19 The presence of estrogen and progesterone receptors in breast carcinomas has long been known to be of significance in evaluating long-term prognosis and therapeutic strategies. The status of breast cancer hormone receptors/molecular subtypes may be influenced by race, age, grade and stage. [20] [21] [22] In general, the ER-positive rates in Western countries are around 70% compared with 60% in Asia. 23 In the present study human epidermal growth factor receptor-2 (HER2) was found to be overexpressed in 40% 21 Triple negative breast cancer (TNBC) is a newly proposed sub-type of breast cancer with poor biological behaviors, high invasiveness and poor prognosis. It cannot benefit from endocrine therapy and HER2 targeted therapy due to the negative ER, negative progesterone receptor PR and negative HER2 24 and chemotherapy is, therefore, the drug of choice for such tumors. Among South Asians/ Bangladeshis in the UK and US, the proportion of hormonereceptor-negative breast cancer is higher than in Caucasians. The prevalence of TNBC was found to be the second highest in South Asians (19%) after Black women (25%). 20, 22 All these data suggest that the hormone receptor status of the Bangladeshi breast cancer population is not vastly different from that in high-income countries.
Conclusion:
The study concluded that half of the Bangladeshi breast cancer patients are ER and PR positive and two in every five cases are Her2/neu overexpressed. However, as the sample size was small, the findings should be interpreted with caution.
